Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant TCX plus protocolized surgery in resectable gastric cancer
NL-OMON20157Phase 2Active, not recruiting
- Sponsor
- Jeroen Bosch Hospital
- Start
- Mar 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Jeroen Bosch Hospital. Primary endpoints: Feasibility and toxicity of neoadjuvant TCX, Efficacy and response rate and 4 more. Started Mar 2008; status: active, not recruiting.
02
Drugs
docetaxelcisplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON20157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20157.